Advertisement
ALC vs SYK
Which Stock Would AI Choose? Alcon (ALC) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Alcon (ALC) raised its 2026 earnings outlook twice after strong second-quarter results, with core diluted EPS (earnings per share) growth guidance lifted to 12%–15%.
- Stryker (SYK) delivered a sharp operational recovery in its latest quarter, with adjusted EPS up nearly 18% year over year, but shares fell after management tightened full-year guidance.
- The two companies operate in different corners of healthcare — eye care versus medical technology — making this a comparison of distinct business models rather than direct competitors.
- Alcon's recent market activity has been driven by new product launches and tariff refunds, while Stryker's has been shaped by cybersecurity recovery and capital-equipment demand.
- Both stocks carry analyst "Hold"-leaning ratings, reflecting balanced risk-reward profiles in the current environment.
Introduction
Investors evaluating healthcare exposure often weigh ALC and SYK as two high-quality but distinctly different medtech franchises. Alcon (ALC) is a Swiss-American leader in eye care, spanning surgical equipment and vision-care products, while Stryker (SYK) is a U.S. medical technology giant focused on orthopaedics, surgical equipment, and neurotechnology. This stock comparison is relevant for traders and long-term investors seeking to understand relative performance, market positioning, and growth drivers across two segments of the medical device industry that rarely move in lockstep.
ALC Overview and Recent Performance
ALC, Alcon, is a global leader in eye care, with two core segments: Surgical (implantables, consumables, and equipment) and Vision Care (contact lenses and ocular health). In its most recent quarter, net sales rose roughly 8% to about $2.78 billion, with core EPS up approximately 10% year over year and beating consensus estimates.
Recent market activity has favored Alcon. The company raised its 2026 core diluted EPS growth guidance to 12%–15% and lifted its core operating margin outlook, helped in part by anticipated U.S. tariff refunds. New product launches — including the Unity surgical platform and the Tryptyr dry-eye franchise — have supported growth, while a one-time, non-cash charge tied to the discontinuation of its PowerVision intraocular lens programs weighed on reported results without affecting cash flow. Sentiment has also been shaped by softness in the broader cataract procedure market and competitive pressure in implantables, factors that temper an otherwise constructive picture.
SYK Overview and Recent Performance
SYK, Stryker, is a diversified medical technology company organized around MedSurg and Neurotechnology, plus Orthopaedics. In its latest quarter, revenue grew 9.4% to about $6.59 billion, and adjusted EPS climbed 17.9% to $3.69, both ahead of expectations. This represented a marked rebound after a first-quarter cybersecurity incident disrupted production and delayed shipments.
Despite the beat, Stryker's shares declined after the company tightened — rather than raised — its full-year guidance, reflecting a cautious stance on the second half. Recovery drivers include record Mako robotic-system installations, broad demand across capital equipment, and a return to consistent plant operations. At the same time, lingering cyber-remediation costs, a supply disruption in its peripheral vascular business, and execution risk around new product ramps have kept sentiment balanced. Recent analyst commentary has flagged moderating U.S. hip and knee trends and a less robust near-term outlook.
Trending AI Robots
For traders who prefer a systematic approach to stock selection, Tickeron's Trending AI Robots page offers a curated view of the platform's AI-driven trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and set of covered securities. Because not every bot suits every market condition, only the strongest and most appropriate bots for the current environment earn a place in the Trending AI Robots section. Exploring the page can help investors identify data-driven approaches that align with their own objectives.
Head-to-Head Comparison
Alcon and Stryker differ most clearly in business model and sector exposure. Alcon is a focused pure-play on eye care, deriving roughly 45% of sales from the United States and carrying meaningful exposure to consumer-adjacent products such as contact lenses and dry-eye treatments. Stryker is a broader medtech platform tied to hospital capital spending and surgical procedure volumes, with a heavier emphasis on orthopaedic implants and robotic-assisted surgery.
On growth, Stryker's latest organic sales growth of about 9% outpaced Alcon's roughly 8% reported growth, and Stryker's scale is larger by a wide margin. However, momentum and sentiment diverge: Alcon has guided higher and seen constructive share-price behavior, while Stryker tightened guidance and saw a post-earnings decline despite stronger headline numbers. Risk profiles also differ — Alcon faces competitive and cataract-market softness, whereas Stryker is working through cyber-remediation costs, vascular supply constraints, and execution demands tied to product launches.
Tickeron AI Verdict
Based on observable trend consistency, stability, and relative positioning, Tickeron's AI would likely lean toward ALC at present. Alcon's repeated upward revisions to its earnings and margin outlook, combined with a steadier near-term sentiment backdrop, present a cleaner trend profile than Stryker's recovery-driven but guidance-constrained setup. That said, the verdict is probabilistic rather than definitive: SYK offers a broader, faster-growing platform with a deep robotics-driven product cycle, and its execution risks could resolve favorably. The relative call ultimately hinges on whether Stryker converts its recovery momentum into sustained guidance raises in the coming quarters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALC is a Hold and SYK is a Hold.
Momentum Indicator for ALC turns positive, indicating new upward trend
ALC saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 57 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALC's RSI Oscillator exited the oversold zone, 19 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 54%.
The Moving Average Convergence Divergence (MACD) for ALC just turned positive on October 09, 2026. Looking at past instances where ALC's MACD turned positive, the stock continued to rise in 31 of 54 cases over the following month. The odds of a continued upward trend are 57%.
Following a +5.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALC advanced for three days, in 181 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for ALC crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
ALC broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALC entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. ALC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.481) is normal, around the industry mean (4.821). P/E Ratio (50.136) is within average values for comparable stocks, (36.081). Projected Growth (PEG Ratio) (1.165) is also within normal values, averaging (4.456). Dividend Yield (0.016) settles around the average of (0.006) among similar stocks. P/S Ratio (2.996) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
SYK's RSI Indicator ascending out of oversold territory
The RSI Indicator for SYK moved out of oversold territory on September 25, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 16 of the 24 cases the stock moved higher. This puts the odds of a move higher at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on SYK as a result. In 52 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on September 28, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in 23 of 45 cases over the following month. The odds of a continued upward trend are 51%.
Following a +4.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 171 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SYK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SYK entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.712) is normal, around the industry mean (2.949). P/E Ratio (30.284) is within average values for comparable stocks, (2.438). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.052). Dividend Yield (0.012) settles around the average of (0.009) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ALC | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 26 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 78 | |
SMR RATING 1..100 | 88 | 52 | |
PRICE GROWTH RATING 1..100 | 69 | 59 | |
P/E GROWTH RATING 1..100 | 11 | 83 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALC's Valuation (70) in the Hospital Or Nursing Management industry is in the same range as SYK (75) in the Medical Specialties industry. This means that ALC’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (78) in the Medical Specialties industry is in the same range as ALC (100) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew similarly to ALC’s over the last 12 months.
SYK's SMR Rating (52) in the Medical Specialties industry is somewhat better than the same rating for ALC (88) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew somewhat faster than ALC’s over the last 12 months.
SYK's Price Growth Rating (59) in the Medical Specialties industry is in the same range as ALC (69) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew similarly to ALC’s over the last 12 months.
ALC's P/E Growth Rating (11) in the Hospital Or Nursing Management industry is significantly better than the same rating for SYK (83) in the Medical Specialties industry. This means that ALC’s stock grew significantly faster than SYK’s over the last 12 months.
| ALC | SYK | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 54% | 4 days ago 67% |
| Stochastic ODDS (%) | 4 days ago 64% | 4 days ago 56% |
| Momentum ODDS (%) | 4 days ago 63% | 4 days ago 57% |
| MACD ODDS (%) | 4 days ago 57% | 4 days ago 51% |
| TrendWeek ODDS (%) | 4 days ago 58% | 4 days ago 56% |
| TrendMonth ODDS (%) | 4 days ago 52% | 4 days ago 50% |
| Advances ODDS (%) | 5 days ago 57% | 4 days ago 56% |
| Declines ODDS (%) | 13 days ago 55% | 6 days ago 52% |
| BollingerBands ODDS (%) | 4 days ago 55% | 4 days ago 70% |
| Aroon ODDS (%) | 4 days ago 56% | 4 days ago 41% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALC’s FA Score shows that 1 FA rating(s) are green while SYK’s FA Score has 0 green FA rating(s).
- ALC’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALC’s TA Score shows that 4 TA indicator(s) are bullish while SYK’s TA Score has 4 bullish TA indicator(s).
- ALC’s TA Score: 4 bullish, 5 bearish.
- SYK’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALC (@Pharmaceuticals: Other) experienced а +3.23% price change this week, while SYK (@Medical/Nursing Services) price change was +6.25% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.96%. For the same industry, the average monthly price growth was -3.54%, and the average quarterly price growth was +4.93%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -5.80%. For the same industry, the average monthly price growth was -10.59%, and the average quarterly price growth was -13.95%.
Reported Earning Dates
ALC is expected to report earnings on Nov 10, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.96% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-5.80% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.